Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
Category: #health  By Saipriya Iyer  Date: 2019-12-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi to acquire biotechnology firm Synthorx for $2.5 billion

Sanofi, a renowned France based multinational pharmaceutical company, reportedly announced that it would be acquiring California based biotechnology firm, Synthorx, for $2.5 billion. Sanofi offered to purchase all outstanding shares of Synthorx in cash for $68 per share, or a premium of 172% to Synthorx’s Dec. 6, 2019 closing price.

Paul Hudson, Chief Executive, Sanofi, reportedly stated that the acquisition fits ideally with the company’s strategy to build high-quality assets and to lead innovation. Hudson further adds that the deal is aligned with the company’s goal to build their oncology franchise with practice changing medicines and new combinations.

As stated by the company’s website, Synthorx is a clinical-stage biotech firm focusing on therapies for people diagnosed with auto immune disorders and cancer. It recorded a net loss of $56.6 million in 2018.

The acquisition is expected to be completed in the first quarter of 2020.

A broad strategy review was conducted by Sanofi under Hudson. Hudson had given initial pointers as to which business the company would focus on during investor day held in Cambridge, Massachusetts on December 10. Furthermore, Hudson also stated that significant changes are being made in the company.

As a precursor to its new growth strategy, Sanofi sold its Seprafilm unit to Baxter International, a medical supply company, for $350 million in cash.

About Sanofi:

Sanofi is a renowned pharmaceutical company headquartered in Paris, France. The company engages in the marketing and manufacturing, research and development of pharmaceutical drugs, it also develops medications over the counter. It covers seven major therapeutic areas like internal medicine, central nervous system, diabetes, oncology, vaccines, thrombosis and cardiovascular.

About Synthorx:

Synthorx is a renowned biotech firm focusing on improving lives of people diagnosed with autoimmune and cancer disorders. The firms leading product, THOR-707, a variation of IL-2 has been developed in multiple tumor types as a single agent combined with an immune checkpoint inhibitor.
 

Source credit: https://www.reuters.com/article/us-sanofi-m-a-synthorx/frances-sanofi-to-buy-biotech-firm-synthorx-for-2-5-billion-idUSKBN1YD0FW



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...